Sign in
Taking peopleNo phase

FIH ITA Study - Vesalius TMVr System for Symptomatic Degenerative Mitral Regurgitation

Key facts

Who runs it
Vesalius Cardiovascular Inc.
Where
Canada1 site in 1 countryChoose a country to see its sites
Trial code
Status
Recruiting
People taking part
5 people, planned
Started
Aug 2026
Expected to end
Apr 2032
Type of study
Interventional
Treatments tested
  • Transcatheter Mitral Valve Repair
Record updated
19 August 2026

Who can take part

Age
19 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 28 criteriaShow less

Who can take part

  • Age ≥ 19 years
  • Moderate to severe (≥3+) or severe (≥4+) degenerative mitral valve regurgitation (per American Society of Echocardiography (ASE) guidelines, depicted in Figure 14)
  • New York Heart Association (NYHA) Functional Class II, III, or Ambulatory (IV)
  • Elevated risk for surgical mitral valve repair: Society of Thoracic Surgery (STS) predicted risk of mortality (PROM) of ≥6% as determined by the STS Risk Calculator for Surgical Repair of Primary Mitral Regurgitation [1], as well as patient operative risk assessment by the Heart Team
  • Suitable anatomy for the Vesalius TMVr System as determined by pre-procedure imaging
  • Willing to adhere to study follow-up schedule for up to 5 years
  • Written informed consent provided

Who cannot take part

  • Anatomy ideally suitable for other approved transcatheter therapy (i.e. TEER candidate)
  • Previous valvular surgery
  • Previous atrial septal surgery
  • Previous endovascular structural procedure(s) and/or device(s) within 6 months
  • Contraindication to anticoagulation / antiplatelet therapy
  • Concomitant severe tricuspid regurgitation
  • Dialysis-dependent renal insufficiency
  • Leaflet perforation
  • Life expectancy <1 year due to non-cardiac comorbidities
  • Presence of other anatomic, comorbid conditions, or other medical conditions that could limit the subject's ability to participate in the clinical investigation or to comply with follow-up requirements, or impact the scientific soundness of the clinical investigation results, in the opinion of the Heart Team
  • LV ejection fraction < 30%
  • Active bacterial endocarditis within 60 days of planned index procedure
  • Body Mass Index (BMI) ≥ 45 kg/m2
  • Severe mitral annular calcification (MAC) prohibiting device implantation
  • Severe annulus or leaflet calcification
  • Patients with sensitivity to nickel or contrast media
  • Absence of conventional medial and lateral papillary muscle groups
  • Femoral vein cannot accommodate a 29 F catheter
  • Contraindication to Transoesophageal echocardiography (TEE)
  • Participation in other clinical investigation
  • Pregnant or planning to become pregnant

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

This first-in-human study evaluates the safety and performance of the Vesalius Transcatheter Mitral Valve Repair (TMVr) System in patients with degenerative mitral regurgitation. The study will enroll patients who are at high or prohibitive risk for conventional surgical repair or replacement of the mitral valve. Participants will receive implantation of the Vesalius TMVr System and will be followed to assess clinical outcomes, device performance, and any adverse events.

The group in the trial

  • Vesalius TMVr SystemTreatment being tested

    Participants in this arm will undergo implantation with the Vesalius Transcatheter Mitral Valve Repair (TMVr) System according to the study protocol. All procedures will be performed by trained interventional cardiologists, and participants will be followed for safety, device performance, and clinical outcomes at predefined intervals.

    Treatment: Transcatheter Mitral Valve Repair

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A First-in-Human Investigational Testing Authorization Study Evaluating the Safety and Performance of the Vesalius Transcatheter Mitral Valve Repair System in Patients With Severe, Symptomatic Degenerative Mitral Regurgitation
Record updated
19 August 2026